Gilead, Moderna Candidates Ramp Up Coronavirus Drug, Vaccine Testing
Summary
On Wednesday, Foster City, CA-based Gilead (NASDAQ: GILD) announced the start of two Phase 3 clinical studies of the drug, a broad-spectrum antiviral called remdesivir, in countries with high numbers of diagnosed cases. To date, only healthy volunteers, people infected with the Ebola virus, and a “small number” of coronavirus patients to whom Gilead has provided the experimental drug as an emergency treatment on a compassionate use basis have received it. Other research into remdesivir as a potential treatment for coronavirus includes two clinical trials in China’s Hubei province, led by the China-Japan Friendship Hospital, which began enrolling patients earlier this month. (The first person enrolled was previously quarantined on the Diamond Princess cruise ship, which earlier this month hosted the highest concentration of coronavirus cases outside of China, where the virus was first identified. The Moderna vaccine trial, which doesn’t have a firm start date, will take place at the Kaiser Permanente Washington Health Research Institute in Seattle, according to a NIAID spokesman.
Classifications
AskAI Classifications
LabelsLinked Companies
